UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000011277 |
|---|---|
| Receipt number | R000013216 |
| Scientific Title | he efficacy of alogliptin to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor and gastroprotective agents |
| Date of disclosure of the study information | 2013/07/26 |
| Last modified on | 2014/10/18 11:43:03 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
he efficacy of alogliptin to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor and gastroprotective agents
Acronym
The efficacy of alogliptin to gastrin and glycemic control
Scientific Title
he efficacy of alogliptin to gastrin and glycemic control in patients with type 2 diabetes under treatment with gastric secretion inhibitor and gastroprotective agents
Scientific Title:Acronym
The efficacy of alogliptin to gastrin and glycemic control
Region
| Japan |
Condition
Condition
Patients with type 2 diabetes
Classification by specialty
| Medicine in general | Gastroenterology | Hepato-biliary-pancreatic medicine |
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
By prescribing alogliptin,examined by drugs that gastric secretion inhibitor and gastroprotective agents,or whether there is a difference in gastrin and glycemic control
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
Changes and %changes in gastrin and HbA1c after 6 months from baseline
Key secondary outcomes
Changes and %changes in the following parameters during the observation period
Body weight
Office blood pressure
Serum creatinine
HDL
TG
LDL
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Alogliptin
Interventions/Control_2
pioglitazone hydrochloride
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Type2 diabetes whose HbA1c is >6.4% under life style intervention and ordinal dosage of SU or metformin or alpha-glucosidase inhibitor treatment
Key exclusion criteria
diabetic ketosis
severe infection
before and after operation patients with severe trauma
past history of allergy against alogliptin
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Syuuji Inoue |
Organization
National Hospital Organization National Kochi Hospital,
Division name
Division of Gastroenterology
Zip code
Address
1-2-25Asakuranisimati,Kochi,Japan
TEL
088-844-3111
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Syuuji Inoue |
Organization
National Hospital Organization National Kochi Hospital, Kochi, Japan
Division name
Division of Gastroenterology
Zip code
Address
1-2-25Asakuranisimati,Kochi,Japan
TEL
Homepage URL
Sponsor or person
Institute
National Hospital Organization National Kochi Hospital,
Institute
Department
Personal name
Funding Source
Organization
Takeda Pharmaceutical Limited
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
独立行政法人国立病院機構高知病院
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 07 | Month | 26 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2013 | Year | 07 | Month | 25 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 07 | Month | 26 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 07 | Month | 25 | Day |
Last modified on
| 2014 | Year | 10 | Month | 18 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013216
